Recurrent Thyroid Gland Carcinoma — Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Citation(s)
Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy